# Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

> **NCT06016920** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nykode Therapeutics ASA** · enrollment: 51 (estimated)

## Conditions studied

- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- HNSCC

## Interventions

- **BIOLOGICAL:** VB10.16
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06016920
- **Lead sponsor:** Nykode Therapeutics ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-19
- **Primary completion:** 2027-09
- **Final completion:** 2028-01
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2024-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016920, "Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06016920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*